A conversation with Sayeh Lavasani, MD, MS, a medical oncologist specializing in breast cancer at the City of Hope Comprehensive Cancer Cente, in Duarte, California, who discusses how clinical pathways are developed and used at the cancer center, how the pathways for patients with HER2-low breast cancer are utilized, recent updates in the HER2-low treatment landscape, the challenges and level of evidence needed to incorporate new therapeutic approaches into the clinical pathway, and the challenges and crafty balancing that’s needed between standardizing treatment decisions across the population and optimizing care for individual patients.

Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression? After taking part in this CME activity, medical oncologists, surgeons, dermatologists, oncology nurses, oncology pharmacists, and other members of the interprofessional team who manage patients with melanoma should be better able to:

Payal Goala, MS, BS, a pre-doctoral fellow at Roswell Park Comprehensive Cancer Center, presented research findings at the 64th annual meeting of the American Society of Hematology (ASH), held December 10–13 in New Orleans, Louisiana. Her work may help address neutropenia and cytokine release syndrome, two serious side effects of chimeric antigen receptor (CAR) T-cell therapy. The research is being hailed as a “significant advancement” in the knowledge of these toxicities and is expected to help patients receiving CAR-T therapy live better lives.

Adenoma detection rate (ADR) is inversely correlated with postcolonoscopy (PC) CRC incidence risk in a fecal immunochemical test (FIT)-based screening program, necessitating adequate colonoscopy quality monitoring in this situation. The likelihood of PCCRC may be considerably decreased by raising endoscopists’ ADR.

An earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy showed that the addition of pembrolizumab to neoadjuvant chemotherapy resulted in a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery. The trial’s main findings on event-free survival have not been published.

The incidence of hospitalization or an emergency department visit (observation for more than 6 hours) was significantly lower among those who received a single dose of pegylated interferon lambda than among those who received a placebo.